- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02317003
Physical Exercise Prescription With PEdometeR in General Practice for Patients With Cardiovascular Risk Factors - PEPPER (PEPPER)
Physical Exercise Prescription With PEdometeR in General Practice for Patients With Cardiovascular Risk Factors - The PEPPER Pragmatic Randomised Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Health benefits of physical activity have been shown to be at least as important as drug therapies in the prevention of cardiovascular diseases in patients with hypertension, hyperlipidaemia or diabetes. However, few strategies have demonstrated efficacy and practicality in the promotion of physical exercise among these high risk patients in general practice.
The PEPPER clinical study is a pragmatic randomised trial over a period of 12 months to evaluate the efficacy, in terms of physical activity level, of an intervention based on structured information delivery according to cognitive and behavioural theories, a personalised written physical activity prescription in number of steps per day, a pedometer, and a pedometer logbook similar to diabetes logbooks, in 35 to 74 year old patients with cardiovascular risks factors. This strategy will be compared to the commonly used oral recommendation of physical activity. The primary outcome is the change in total energy expenditure measured by accelerometry over a 7-day period. Secondary outcomes include changes in physical activity levels (International Physical Activity Questionnaire), quality of life (SF-36), blood pressure, weight, waist circumference, perceived obstacles to physical activity, and patient and doctors compliance with the suggested strategy. 140 patients will be recruited and followed up in 15 GP practices. Measures will be assessed at baseline, at 3 months and at 12 months (end of intervention).
The results of the PEPPER study are expected at the end of 2016. If the intervention proves effective in increasing durably the level of physical activity, this relatively simple and cheap strategy could help decrease the occurrence of cardiovascular events in a large high-risk population seen in general practice.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Angers, France, 49933
- Angers University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients consulting their general practitioner for a non-urgent matter
- with regular follow-up every 3 months for hypertension, hypercholesterolaemia or non insulin dependent type 2 diabetes.
- judged insufficiently active by their general practitioner based on negative answers to the questions : "Do you practice a physical activity or cycling more than an hour per week?" and "Does your occupation involve physical exertion?"
Exclusion Criteria:
- contraindication to moderate physical activity,
- non autonomous for walking,
- with cognitive or psychiatric impairment limiting the full understanding of the study,
- suffering from another limiting disease (coronary insufficiency, chronic cardiac failure, etc),
- who don't speak French,
- refusing to participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention PPIL
Intervention delivered by the family doctor and based on structured information delivery according to cognitive and behavioural theories, a personalised written physical activity prescription in number of steps per day, a pedometer, and a pedometer logbook similar to diabetes logbooks.
|
Other Names:
|
Active Comparator: Control OR
Oral recommendation of physical exercise delivered by the family doctor.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in total energy expenditure by accelerometry at 3 months compared to baseline
Time Frame: baseline and 12 weeks
|
The total energy expenditure is measured with a wGT3x-BT Actigraph accelerometer worn at the belt during 7 consecutive days from morning to evening.
It is measured in Metabolic Equivalent Task-Minutes per Week.
|
baseline and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in total energy expenditure by accelerometry at 12 months compared to baseline
Time Frame: baseline and 52 weeks
|
The total energy expenditure is measured with a wGT3x-BT Actigraph accelerometer worn at the belt during 7 consecutive days from morning to evening.
It is measured in Metabolic Equivalent Task-Minutes per Week.
|
baseline and 52 weeks
|
Change in total energy expenditure by questionnaire at 3 months compared to baseline
Time Frame: baseline and 12 weeks
|
The total energy expenditure is calculated with the self-administered International Physical Activity Questionaire (IPAQ) short version covering the past 7 days.
It is expressed in Metabolic Equivalent Task-Minutes per Week.
|
baseline and 12 weeks
|
Change in total energy expenditure by questionnaire at 12 months compared to baseline
Time Frame: baseline and 52 weeks
|
The total energy expenditure is calculated with the self-administered International Physical Activity Questionaire (IPAQ) short version covering the past 7 days.
It is expressed in Metabolic Equivalent Task-Minutes per Week.
|
baseline and 52 weeks
|
Change in quality of life at 3 months compared to baseline
Time Frame: baseline and 12 weeks
|
Change in quality of life as measured by the self-administered Short Form 36 questionnaire
|
baseline and 12 weeks
|
Change in quality of life at 12 months compared to baseline
Time Frame: baseline and 52 weeks
|
Change in quality of life as measured by the self-administered Short Form 36 questionnaire
|
baseline and 52 weeks
|
Change in waist circumference at 3 months compared to baseline
Time Frame: baseline and 12 weeks
|
baseline and 12 weeks
|
|
Change in waist circumference at 12 months compared to baseline
Time Frame: baseline and 52 weeks
|
baseline and 52 weeks
|
|
Change in weight at 3 months compared to baseline
Time Frame: baseline and 12 weeks
|
baseline and 12 weeks
|
|
Change in weight at 12 months compared to baseline
Time Frame: baseline and 52 weeks
|
baseline and 52 weeks
|
|
Change in arterial blood pressure at 3 months compared to baseline
Time Frame: baseline and 12 weeks
|
baseline and 12 weeks
|
|
Change in arterial blood pressure at 12 months compared to baseline
Time Frame: baseline and 52 weeks
|
baseline and 52 weeks
|
|
Perceived obstacles to physical exercise
Time Frame: 52 weeks
|
Perceived obstacles to physical exercise as measured by the Determinant of Physical Activity Questionnaire (DPAQ)
|
52 weeks
|
Adherence of doctors and patients to the suggested strategy
Time Frame: 12 weeks
|
12 weeks
|
|
Adherence of doctors and patients to the suggested strategy
Time Frame: 52 weeks
|
52 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Denise Jolivot, MD, University Hospital, Angers
- Principal Investigator: Laurent Connan, MD, Medical School, Angers
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHU-P 2014-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
Nanjing Medical UniversityRecruiting
-
Centre Hospitalier Universitaire de la RéunionRecruitingCardiovascular DiseaseFrance
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular DiseaseUnited States
Clinical Trials on Intervention PPIL
-
Biolux Research Holdings, Inc.TerminatedOrthodontic Tooth MovementCanada
-
University of California, San FranciscoNational Cancer Institute (NCI)CompletedColorectal Carcinoma | Healthy Subject | Health Status UnknownUnited States
-
University of FloridaCompletedSensitivityUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Institute on Minority Health and...RecruitingHuman Papillomavirus InfectionUnited States
-
Ohio State University Comprehensive Cancer CenterCompleted
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnCancer Survivor | Peripheral Sensory Neuropathy
-
Nottingham Trent UniversityUnknownOverweight and ObesityUnited Kingdom
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...American Cancer Society, Inc.Completed
-
Vanderbilt UniversityAgency for Healthcare Research and Quality (AHRQ)Completed